At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BJDX Bluejay Diagnostics Inc
Trading 08-14 11:03:41 EDT
1.04
-0.02
-1.90%
High1.09Low1.03Vol65.00K
Open1.08D1 Closing1.06Amplitude5.66%
Mkt Cap4.65MTradable Cap4.48MTotal Shares4.47M
T/O68.32KT/O Rate1.51%Tradable Shares4.31M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Bluejay Advances Symphony Platform, Strengthens Cash Position
TIPRANKS  ·  08-13 20:17
Bluejay Advances Symphony Platform, Strengthens Cash Position
Bluejay Diagnostics Q2 EPS $(1.12) Up From $(5.64) YoY
Benzinga Earnings  ·  08-13 18:17
Bluejay Diagnostics Q2 EPS $(1.12) Up From $(5.64) YoY
Bluejay Diagnostics Says SYMON-II Pivotal Study Completes Enrollment of 750 Patients for Symphony IL-6 Test
Reuters  ·  08-13 18:04
Bluejay Diagnostics Says SYMON-II Pivotal Study Completes Enrollment of 750 Patients for Symphony IL-6 Test
Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ Il-6 Toward Regulatory Submission and Commercialization
THOMSON REUTERS  ·  08-13 18:00
Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ Il-6 Toward Regulatory Submission and Commercialization
Press Release: Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony(TM) IL-6 Toward Regulatory Submission and Commercialization
Dow Jones  ·  08-13 18:00
Press Release: Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony(TM) IL-6 Toward Regulatory Submission and Commercialization
Bluejay Net Loss Widens to $2.32 Million in Q2 FY26
Reuters  ·  08-13 04:12
Bluejay Net Loss Widens to $2.32 Million in Q2 FY26
Top Premarket Gainers
MT Newswires Live  ·  08-05
Top Premarket Gainers
Bluejay Diagnostics Completes Enrollment in SYMON-II Sepsis Study
TIPRANKS  ·  07-23
Bluejay Diagnostics Completes Enrollment in SYMON-II Sepsis Study
Bluejay Diagnostics Initial Beneficial Ownership Statement Names Bank of America as 10% Owner
Reuters  ·  07-23
Bluejay Diagnostics Initial Beneficial Ownership Statement Names Bank of America as 10% Owner
Bluejay Diagnostics completes enrollment in SYMON-II study
TIPRANKS  ·  07-21
Bluejay Diagnostics completes enrollment in SYMON-II study
Bluejay Diagnostics Announces Symon-ii Sepsis Study Enrollment Completion
Reuters  ·  07-21
Bluejay Diagnostics Announces Symon-ii Sepsis Study Enrollment Completion
Bluejay Diagnostics - Preliminary Symon-ii Data Show 17% 28-day Mortality Rate
THOMSON REUTERS  ·  07-21
Bluejay Diagnostics - Preliminary Symon-ii Data Show 17% 28-day Mortality Rate
Bluejay Diagnostics Announces Successful Completion of Enrollment in the Symon-ii Multicenter Clinical Validation Study
THOMSON REUTERS  ·  07-21
Bluejay Diagnostics Announces Successful Completion of Enrollment in the Symon-ii Multicenter Clinical Validation Study
HRT Financial LP Sells 34,938 Bluejay Diagnostics Shares for $48,913.20
Reuters  ·  07-14
HRT Financial LP Sells 34,938 Bluejay Diagnostics Shares for $48,913.20
Bluejay Diagnostics Initial Beneficial Ownership Filing Shows HRT Financial LP Stake of 126,993 Shares
Reuters  ·  07-14
Bluejay Diagnostics Initial Beneficial Ownership Filing Shows HRT Financial LP Stake of 126,993 Shares
Bluejay Diagnostics Advances Symphony IL-6 Sepsis Pilot, Keeping Investor Focus on ER Diagnostics
TIPRANKS  ·  07-03
Bluejay Diagnostics Advances Symphony IL-6 Sepsis Pilot, Keeping Investor Focus on ER Diagnostics
Bluejay Diagnostics files to sell 11.22M shares of common stock for holders
TIPRANKS  ·  06-18
Bluejay Diagnostics files to sell 11.22M shares of common stock for holders
Bluejay Diagnostics Shareholders Approve Stock Plan and Flexibility
TIPRANKS  ·  06-10
Bluejay Diagnostics Shareholders Approve Stock Plan and Flexibility
Bluejay Diagnostics shareholders approve 600,000-share increase to 2021 stock plan reserve
Reuters  ·  06-10
Bluejay Diagnostics shareholders approve 600,000-share increase to 2021 stock plan reserve
Bluejay Diagnostics Completes Private Placement to Extend Runway
TIPRANKS  ·  06-09
Bluejay Diagnostics Completes Private Placement to Extend Runway
No data available

Introduction

Company Name.
Bluejay Diagnostics Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers Symphony platform, a technology platform comprising Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. It also provides ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 test for the monitoring of disease progression in critical care settings. Further, it develops cardiac biomarkers, such as hsTNT and NT pro-BNP, as well as other tests using the Symphony platform. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Issue price:
--